Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Seelos Therapeutics, Inc. (NEXM) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Seelos Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1017491.
Total stock buying since 2014: $7,336,075.
Total stock sales since 2014: $0.
Total stock option exercises since 2014: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 158,757 | $200,263 | 0 | $0 | 0 | $0 |
| 2022 | 16,000 | $9,792 | 0 | $0 | 0 | $0 |
| 2018 | 0 | $0 | 0 | $0 | 81,775 | $0 |
| 2017 | 6,104 | $9,949 | 0 | $0 | 0 | $0 |
| 2016 | 7,954,547 | $7,000,000 | 0 | $0 | 0 | $0 |
| 2014 | 82,000 | $116,071 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-12 | 75,757 | $99,999 | 0 | $0 | 0 | $0 |
| 2023-11 | 83,000 | $100,264 | 0 | $0 | 0 | $0 |
| 2022-06 | 16,000 | $9,792 | 0 | $0 | 0 | $0 |
| 2018-08 | 0 | $0 | 0 | $0 | 81,775 | $0 |
| 2017-08 | 6,104 | $9,949 | 0 | $0 | 0 | $0 |
| 2016-03 | 6,647,728 | $5,850,000 | 0 | $0 | 0 | $0 |
| 2016-01 | 1,306,819 | $1,150,000 | 0 | $0 | 0 | $0 |
| 2014-12 | 20,000 | $20,700 | 0 | $0 | 0 | $0 |
| 2014-10 | 62,000 | $95,371 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-12-01 | Mehra Raj (See Remarks) | Buy | 75,757 | 1.32 | 99,999 |
| 2023-11-30 | Golembiewski Michael Joseph (Chief Financial Officer) | Buy | 83,000 | 1.21 | 100,264 |
| 2022-06-01 | O'connor Daniel J. | Buy | 16,000 | .61 | 9,792 |
| 2018-08-30 | Dorsey Brian | Option Ex | 81,775 | .00 | 0 |
| 2017-08-31 | Sarissa Capital Offshore Master Fund Lp | Buy | 6,104 | 1.63 | 9,949 |
| 2016-03-03 | Sarissa Capital Offshore Master Fund Lp | Buy | 6,647,728 | .88 | 5,850,000 |
| 2016-01-12 | Sarissa Capital Offshore Master Fund Lp (10% Owner) | Buy | 1,306,819 | .88 | 1,150,000 |
| 2014-12-29 | Dorsey Brian (Chief Development Officer) | Buy | 10,000 | 1.05 | 10,480 |
| 2014-12-22 | Pascoe Richard W (Chief Executive Officer) | Buy | 10,000 | 1.02 | 10,220 |
| 2014-10-23 | Smith Sandford D | Buy | 18,200 | 1.59 | 28,992 |
| 2014-10-22 | Ray Rusty | Buy | 3,500 | 1.50 | 5,250 |
| 2014-10-22 | Pascoe Richard W (Chief Executive Officer) | Buy | 12,000 | 1.51 | 18,120 |
| 2014-10-22 | Smith Sandford D | Buy | 8,300 | 1.52 | 12,649 |
| 2014-10-22 | Wierenga Wendall | Buy | 20,000 | 1.52 | 30,360 |
Insider trading activities including stock purchases, stock sales, and option exercises of NEXM listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Seelos Therapeutics, Inc. (symbol NEXM, CIK number 1017491) see the Securities and Exchange Commission (SEC) website.